Insights from Ocular Gene Therapy Clinics in Europe

Three Years of Real-World Experience with Voretigene Neparvovec▼

8th & 15th June 2022 at 19:30–21:00 hours CEST.

To register please login or create an account.

Voretigene neparvovec is the first gene therapy made broadly available to patients, and it has been over three years since the first patient in Europe was treated with this breakthrough medicine. In three years, voretigene neparvovec has had a deep impact on clinical practice in Inherited Retinal Dystrophies and has transformed the daily life of dozens of patients.

In this unique webinar series, we asked leading experts in Europe how gene therapy has revolutionized their field of practice, and whether the first ocular gene therapy keeps its promises beyond clinical trials.

In a series of short talks, we explore how treatment with gene therapy is carried out in real-world clinical practice, the unique challenges and opportunities offered by ocular gene therapy, and how voretigene neparvovec has impacted on the life of patients in need across Europe.

 

This educational event consists of two webcasts:

Insights from Ocular Gene Therapy Clinics in Europe - Three Years of Real-World Experience with Voretigene Neparvovec

Part 1: France, Germany and Italy – 8th June 2022

With experts and experience from multiple countries, this webcast will discuss among other things:

  • Insights on real-world experience with ocular gene therapy from France, Germany, Italy
  • The EpiGenRet project in France – a collaboration with Europe to improve the IRD patient journey
  • An update on the PERCEIVE post-approval safety study for voretigene neparvovec

Insights from Ocular Gene Therapy Clinics in Europe - Three Years of Real-World Experience with Voretigene Neparvovec

Part 2: Belgium, Croatia, Denmark, the Netherlands, the United Kingdom – 15th June 2022

With experts and experience from multiple countries, this webcast will discuss among other things:

  • Insights on real-world experience with ocular gene therapy from Belgium, Croatia, Denmark, the Netherlands and the UK.
  • The genetic diagnosis pathway for patients with inherited retinal dystrophies
  • A new approach in gene sequencing

Date

These webcasts will be broadcast on:

  • 8th June 2022 at 19:3021:00 hours CEST
  • 15th June 2022 at 19:3021:00 hours CEST

Easy registration

Create an account or log in with your existing account on this website.

Audience

This webcast is primarily intended for ophthalmologists, geneticists and pediatricians. Other healthcare professionals with an interest in Ocular Gene Therapy all over the world are also welcome to join. The webcast will be held in English.

Free webcast

Participation in this webcast is free of charge.

Questions?

If you have any questions, please send an email to nascholing@springer.com.

 

This webcast is sponsored by Novartis Pharma AG, CH-4056

200997

In the context of GDPR, Springer complies with the laws and regulations as laid down by this law. Organization of the webcast implies the processing of healthcare professionals' data, including for sending invitations, ensuring registration, and managing attendance. The data controller for this data processing is Springer, which will ensure compliance with all applicable laws. If you want to know more about the applicable privacy conditions and your available rights, please click here: Springer Healthcare
For the avoidance of doubt, Novartis will only receive aggregated reports with number of attendees per country.

 

DISCLAIMER TEXT

  • This event is organized and funded by Novartis Pharma AG
  • These presentations are intended for non-promotional scientific purposes only and may contain information on products or indications currently under investigation and/or that have not been approved by the regulatory authorities
  • The opinions and views expressed in this slide deck are those of the presenters and do not necessarily constitute the opinions or recommendations of Novartis
  • These presentations are accurate at the time of recording
  • Any data about non-Novartis products are based on publicly available information at the time of recording
  • Prescribing information may vary depending on local health authority approval in each country. Before prescribing any product, always refer to the SmPC or product information approved in your local country
  • Permissions for all content within have been received from each copyright holder for presentations as part of the Webinar: Three Years of Real-World Experience with Voretigene Neparvovec – Insights from Ocular Gene Therapy Clinics in Europe. Separate use, adaptation, and/or translation requires application for specific use permissions from each copyright holder
  • Please note that the recording, reproduction, distribution including on social media, public communication and/or content modification are not allowed. The content is Novartis Pharma AG proprietary and copyrighted content.

 

To continue reading, please log in

Log in with your BSL Account

Log in

Forgot your password?

No BSL Account yet? Please register

Register

More information on BSL Accounts.